Tags

Type your tag names separated by a space and hit enter

Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Mov Disord. 2009 Apr 30; 24(6):929-32.MD

Abstract

Homocysteine, cysteine, and cysteinyl-glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl-glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [micromol/L] when compared with PD patients with tHcy above 15. Cysteinyl-glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine.

Authors+Show Affiliations

Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstrasse 1, Berlin,Germany. th.mueller@alexius.de orNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

19243072

Citation

Müller, Thomas, and Wilfried Kuhn. "Cysteine Elevation in Levodopa-treated Patients With Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 24, no. 6, 2009, pp. 929-32.
Müller T, Kuhn W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord. 2009;24(6):929-32.
Müller, T., & Kuhn, W. (2009). Cysteine elevation in levodopa-treated patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 24(6), 929-32. https://doi.org/10.1002/mds.22482
Müller T, Kuhn W. Cysteine Elevation in Levodopa-treated Patients With Parkinson's Disease. Mov Disord. 2009 Apr 30;24(6):929-32. PubMed PMID: 19243072.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cysteine elevation in levodopa-treated patients with Parkinson's disease. AU - Müller,Thomas, AU - Kuhn,Wilfried, PY - 2009/2/27/entrez PY - 2009/2/27/pubmed PY - 2009/7/30/medline SP - 929 EP - 32 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 24 IS - 6 N2 - Homocysteine, cysteine, and cysteinyl-glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cysteine, and cysteinyl-glycine in PD patients and healthy controls. Cysteine levels were significant lower in controls and PD patients with tHcy below the treshold of 15 [micromol/L] when compared with PD patients with tHcy above 15. Cysteinyl-glycine did not significantly differ between the three cohorts. Significant associations appeared between tHcys and cysteine in PD patients. tHcy and cysteine concentrations correlated to LD/DCI intake and severity of PD. The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls. The correlation outcomes support the view that LD/DCI intake may also increase cysteine. SN - 1531-8257 UR - https://www.unboundmedicine.com/medline/citation/19243072/Cysteine_elevation_in_levodopa_treated_patients_with_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.22482 DB - PRIME DP - Unbound Medicine ER -